Monitor the Phase 2b LAKE trial SSRE analysis expected early Q1 2027 and the initiation of the non-IPF ILD Phase 2 trial in Q1 2027. Topline data from the Phase 3 OCEAN-2 trial is expected in H2 2027, a key catalyst.
Drug in focus
TRVI drug pipeline →Haduvio
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 trials succeed, a New Drug Application submission could occur in 2028-2029, with potential FDA approval and launch in 2029-2030 for the IPF chronic cough indication, assuming standard review timelines.
- Next catalyst
- None dated
What to watchThe next major catalyst is topline data from the Phase 3 OCEAN-1 trial in IPF-related chronic cough, expected in 2027. Positive data would validate the Phase 2b signal and likely drive the stock toward the $28 mean analyst target; negative data would be a severe blow given Haduvio is Trevi's only pipeline asset. A Phase 2 start in non-IPF ILD chronic cough is planned for Q1 2027, and the cash runway into 2030 eliminates near-term financing risk.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $14.91entry
- T+1 · 6d ago −0.64%α −1.96% · $14.82
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Trevi Therapeutics reported a Q3 2026 net loss of $21.5 million, wider than the $11.8 million loss in Q3 2025, driven by increased R&D spending on Phase 3 OCEAN trials. The company highlighted FDA alignment on the non-IPF ILD program, initiation of the Phase 3 OCEAN-2 trial, and a USPTO Notice of Allowance extending patent protection to 2041. Cash runway into 2030 supports key milestones.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $21.5 million vs $11.8 million in Q3 2025
- Cash, cash equivalents and marketable securities of $299.4 million at September 30, 2026
- Phase 3 OCEAN-2 trial initiated in Q3 2026; both OCEAN trials actively recruiting
- Positive FDA meeting on non-IPF ILD program; Phase 2 dose-ranging trial expected Q1 2027
- USPTO Notice of Allowance for patent covering nalbuphine ER dosing in hepatically impaired patients with non-IPF ILD-related chronic cough, expiring 2041
- Phase 2b LAKE trial in RCC progressing; SSRE analysis expected early Q1 2027
- R&D expenses increased to $19.1 million from $10.1 million year-over-year
- Cash runway expected into 2030
Financial Impact
Net loss widened by $9.7 million year-over-year; cash position increased to $299.4 million from $171.8 million at Q1 2026 end, reflecting the ~$162M April 2026 offering
Risk Factors
- Clinical trial enrollment and data readout risks across three programs
- Net loss widening as R&D spending increases with multiple active trials
- No FDA-approved therapies in target indications; regulatory path remains uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-453670 |
| Document: trvi-20261109.htm | 0001193125-26-453670 |
| Document: 0001193125-26-453670-index-headers.html | 0001193125-26-453670 |
| Document: 0001193125-26-453670-index.html | 0001193125-26-453670 |
| Document: 0001193125-26-453670.txt | 0001193125-26-453670 |
| 8-K Data (Synthetic) | 0001193125-26-453670 |
Track record
12 reports on TRVI
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +15.38% at T+60 after the Mar 9, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 4/10 Viewing Entry $14.91 Now $13.29 −10.87% settles Dec 9
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
- Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
- Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
- Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
- Apr 16, 202630w ago Press Release Neutral 6/10 Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
- Mar 17, 202634w ago Press Release Mixed 6/10 Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers